Star Equity Holdings, Inc. (STRR)
USD 2.36
(-2.88%)
USD 2.36
(-2.88%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.68 Million USD | 39.82% |
| 2022 | -1.34 Million USD | 69.85% |
| 2021 | -3.03 Million USD | -506.21% |
| 2020 | 6.15 Million USD | -420.39% |
| 2019 | 6.37 Million USD | 118.12% |
| 2018 | 4.05 Million USD | -430.97% |
| 2017 | 4.74 Million USD | -107.11% |
| 2016 | 15.16 Million USD | 79.21% |
| 2015 | 6.55 Million USD | -8.42% |
| 2014 | 5.14 Million USD | 479.84% |
| 2013 | 2.24 Million USD | 121.07% |
| 2012 | -2.79 Million USD | -298.26% |
| 2011 | -246 Thousand USD | 54.24% |
| 2010 | -1.96 Million USD | -128.0% |
| 2009 | 5.79 Million USD | 48.13% |
| 2008 | -426 Thousand USD | 61.86% |
| 2007 | 2.32 Million USD | 170.35% |
| 2006 | -3.5 Million USD | 39.12% |
| 2005 | -5.73 Million USD | -245.52% |
| 2004 | 4.28 Million USD | 30.97% |
| 2003 | 2.97 Million USD | 143.08% |
| 2002 | -6.89 Million USD | -299.26% |
| 2001 | 3.46 Million USD | 127.16% |
| 2000 | -12.74 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -2.27 Million USD | -1072.16% |
| 2024 Q2 | -2.97 Million USD | -28.32% |
| 2023 Q4 | 167 Thousand USD | 115.29% |
| 2023 Q3 | -1.09 Million USD | 32.0% |
| 2023 FY | - USD | 39.82% |
| 2023 Q1 | 1.47 Million USD | -42.6% |
| 2023 Q2 | -1.6 Million USD | -208.96% |
| 2022 FY | - USD | 69.85% |
| 2022 Q1 | -2.13 Million USD | -403.78% |
| 2022 Q2 | -323 Thousand USD | 84.84% |
| 2022 Q3 | -1.18 Million USD | -268.11% |
| 2022 Q4 | 2.56 Million USD | 315.98% |
| 2021 Q3 | -1.02 Million USD | -46.28% |
| 2021 Q2 | -698 Thousand USD | -176.98% |
| 2021 FY | - USD | -506.21% |
| 2021 Q1 | -252 Thousand USD | -136.31% |
| 2021 Q4 | -423 Thousand USD | 58.57% |
| 2020 FY | - USD | -420.39% |
| 2020 Q2 | 1.52 Million USD | 193.48% |
| 2020 Q3 | -596 Thousand USD | -139.18% |
| 2020 Q4 | 694 Thousand USD | 216.44% |
| 2020 Q1 | -1.62 Million USD | -251.49% |
| 2019 FY | - USD | 118.12% |
| 2019 Q4 | 1.07 Million USD | -50.39% |
| 2019 Q1 | -1.05 Million USD | -1.06% |
| 2019 Q2 | 1.36 Million USD | 230.38% |
| 2019 Q3 | 2.16 Million USD | 58.14% |
| 2018 Q4 | -1.03 Million USD | -155.03% |
| 2018 Q3 | 1.88 Million USD | -36.92% |
| 2018 FY | - USD | -430.97% |
| 2018 Q1 | -1.26 Million USD | -306.68% |
| 2018 Q2 | 2.99 Million USD | 335.86% |
| 2017 Q1 | -397 Thousand USD | -113.15% |
| 2017 FY | - USD | -107.11% |
| 2017 Q4 | 614 Thousand USD | -88.34% |
| 2017 Q3 | 5.26 Million USD | 240.69% |
| 2017 Q2 | 1.54 Million USD | 489.42% |
| 2016 Q1 | 1.98 Million USD | 211.11% |
| 2016 Q4 | 3.02 Million USD | 259.95% |
| 2016 Q3 | 839 Thousand USD | -57.88% |
| 2016 FY | - USD | 79.21% |
| 2016 Q2 | 1.99 Million USD | 0.2% |
| 2015 Q2 | 1.77 Million USD | 166.87% |
| 2015 FY | - USD | -8.42% |
| 2015 Q4 | 639 Thousand USD | -41.48% |
| 2015 Q1 | 664 Thousand USD | -30.4% |
| 2015 Q3 | 1.09 Million USD | -38.37% |
| 2014 Q1 | 369 Thousand USD | -58.02% |
| 2014 Q2 | 1.08 Million USD | 193.22% |
| 2014 FY | - USD | 479.84% |
| 2014 Q4 | 954 Thousand USD | -21.74% |
| 2014 Q3 | 1.21 Million USD | 12.66% |
| 2013 Q2 | 477 Thousand USD | 418.48% |
| 2013 FY | - USD | 121.07% |
| 2013 Q4 | 879 Thousand USD | -38.57% |
| 2013 Q3 | 1.43 Million USD | 200.0% |
| 2013 Q1 | 92 Thousand USD | 107.35% |
| 2012 FY | - USD | -298.26% |
| 2012 Q3 | -679 Thousand USD | -96.24% |
| 2012 Q2 | -346 Thousand USD | 49.93% |
| 2012 Q1 | -691 Thousand USD | 61.76% |
| 2012 Q4 | -1.25 Million USD | -84.24% |
| 2011 Q1 | 244 Thousand USD | -41.2% |
| 2011 FY | - USD | 54.24% |
| 2011 Q4 | -1.8 Million USD | -444.85% |
| 2011 Q3 | 524 Thousand USD | -15.35% |
| 2011 Q2 | 619 Thousand USD | 153.69% |
| 2010 FY | - USD | -128.0% |
| 2010 Q1 | -219 Thousand USD | -119.08% |
| 2010 Q4 | 415 Thousand USD | 189.83% |
| 2010 Q3 | -462 Thousand USD | 66.25% |
| 2010 Q2 | -1.36 Million USD | -525.11% |
| 2009 FY | - USD | 48.13% |
| 2009 Q2 | 1.89 Million USD | 19.22% |
| 2009 Q3 | 1.18 Million USD | -37.26% |
| 2009 Q1 | 1.58 Million USD | -47.92% |
| 2009 Q4 | 1.14 Million USD | -3.29% |
| 2008 Q1 | -121 Thousand USD | -125.91% |
| 2008 Q2 | 245 Thousand USD | 302.48% |
| 2008 Q3 | 755 Thousand USD | 208.16% |
| 2008 Q4 | 3.04 Million USD | 303.58% |
| 2008 FY | - USD | 61.86% |
| 2007 Q4 | 467 Thousand USD | -4.69% |
| 2007 Q1 | 441 Thousand USD | 9.7% |
| 2007 Q2 | 1.02 Million USD | 132.88% |
| 2007 FY | - USD | 170.35% |
| 2007 Q3 | 490 Thousand USD | -52.29% |
| 2006 Q2 | -362 Thousand USD | 80.9% |
| 2006 Q3 | -1.59 Million USD | -339.78% |
| 2006 FY | - USD | 39.12% |
| 2006 Q1 | -1.89 Million USD | -61.14% |
| 2006 Q4 | 402 Thousand USD | 125.25% |
| 2005 Q3 | -2.07 Million USD | 5.43% |
| 2005 Q4 | -1.17 Million USD | 43.22% |
| 2005 FY | - USD | -245.52% |
| 2005 Q1 | -223 Thousand USD | -129.09% |
| 2005 Q2 | -2.19 Million USD | -882.06% |
| 2004 Q4 | 766.67 Thousand USD | -33.8% |
| 2004 Q2 | 1.12 Million USD | 32.71% |
| 2004 FY | - USD | 30.97% |
| 2004 Q3 | 1.15 Million USD | 3.29% |
| 2004 Q1 | 844.89 Thousand USD | 0.0% |
| 2003 Q2 | 3.16 Million USD | 8.65% |
| 2003 Q1 | 2.91 Million USD | 0.0% |
| 2003 FY | - USD | 143.08% |
| 2002 FY | - USD | -299.26% |
| 2001 FY | - USD | 127.16% |
| 2000 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | 99.21% |
| Prenetics Global Limited | -47.89 Million USD | 96.478% |
| CareDx, Inc | -89.65 Million USD | 98.118% |
| Exact Sciences Corporation | 41.87 Million USD | 104.029% |
| Exagen Inc. | -19.15 Million USD | 91.192% |
| Inotiv, Inc. | -26.5 Million USD | 93.635% |
| Guardant Health, Inc. | -433.3 Million USD | 99.611% |
| Biodesix, Inc. | -37.1 Million USD | 95.453% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | 32.117% |
| Precipio, Inc. | -4.31 Million USD | 60.931% |
| iSpecimen Inc. | -9.1 Million USD | 81.469% |
| Natera, Inc. | -383.27 Million USD | 99.56% |
| Aspira Women's Health Inc. | -16.49 Million USD | 89.77% |
| Standard BioTools Inc. | -54.45 Million USD | 96.902% |
| 23andMe Holding Co. | -291.87 Million USD | 99.422% |
| Castle Biosciences, Inc. | -45.02 Million USD | 96.253% |
| Personalis, Inc. | -96.8 Million USD | 98.257% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 98.565% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | 82.411% |
| OpGen, Inc. | -29.51 Million USD | 94.283% |
| T2 Biosystems, Inc. | -43.87 Million USD | 96.155% |
| Myriad Genetics, Inc. | -67.8 Million USD | 97.512% |
| ICON Public Limited Company | 1.63 Billion USD | 100.103% |
| NeoGenomics, Inc. | -17.6 Million USD | 90.419% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -0.0% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 100.139% |
| RadNet, Inc. | 292.78 Million USD | 100.576% |
| MDxHealth SA | -30.46 Million USD | 94.463% |
| Psychemedics Corporation | -251 Thousand USD | -572.112% |
| Illumina, Inc. | -608 Million USD | 99.723% |
| Check-Cap Ltd. | -17.64 Million USD | 90.441% |
| Twist Bioscience Corporation | -176.7 Million USD | 99.045% |
| DarioHealth Corp. | -53.49 Million USD | 96.846% |
| Fulgent Genetics, Inc. | -46.55 Million USD | 96.376% |
| Sera Prognostics, Inc. | -35.28 Million USD | 95.219% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | 82.759% |
| OPKO Health, Inc. | -65.51 Million USD | 97.425% |
| Medpace Holdings, Inc. | 363.15 Million USD | 100.465% |
| Neogen Corporation | 182.59 Million USD | 100.924% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | 80.853% |
| Prenetics Global Limited | -47.89 Million USD | 96.478% |
| Mainz Biomed B.V. | -25.01 Million USD | 93.255% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | 77.888% |
| Trinity Biotech plc | -24.09 Million USD | 92.999% |
| Neuronetics, Inc. | -22.75 Million USD | 92.588% |
| Sotera Health Company | 514.14 Million USD | 100.328% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | 77.888% |